Managing anemia in patients with chronic kidney disease - Veterinary Medicine
  • SEARCH:
Medicine Center
DVM Veterinary Medicine Featuring Information from:

ADVERTISEMENT

Managing anemia in patients with chronic kidney disease
Anemia reduces quality of life in cats and dogs with renal disease. Erythropoiesis-stimulating agents, iron supplementation, gastrointestinal protectants, and other treatments may help.


VETERINARY MEDICINE


REFERENCES

1. Elliott J, Barber PJ. Feline chronic renal failure: clinical findings in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 1998;39:78-85.

2. DiBartola SP, Rutgers HC, Zack PM, et al. Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973-1984). J Am Vet Med Assoc 1987;190(9):1196-1202.

3. Cowgill LD. Pathophysiology and management of anemia in chronic progressive renal failure. Semin Vet Med Surg (Small Anim) 1992;7(3):175-182.

4. Fishbane SB, Barry M. Hematologic aspects of kidney disease. In: Brenner BM, ed. Brenner and Rector's the kidney. Philadelphia, PA: Saunders Elsevier, 2008;1733-1744.

5. Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev 2008;19:145-155.

6. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622-630.

7. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-148.

8. Semenza GL, Agani F, Booth G, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997;51(2):553-555.

9. Semenza GL. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol Oncol Clin North Am 1994;8:863-864.

10. Zhu H, Bunn HF. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 1999;115(2):239-247.

11. Lulich JP, Osborne CA, O'Brien TD, et al. Feline renal failure: questions, answers, questions. Compend Contin Educ Pract Vet 1992;14(2):127-153.

12. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.

13. Erslev AJ, Besarab A. The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 1995;126(3):283-286.

14. Bonomini M, Sirolli V. Uremic toxicity and anemia. J Nephrol 2003;16(1):21-28.

15. Miguel A, Miguel A, Linares M, et al. Evidence of an increased susceptibility to lipid peroxidation in red blood cells of chronic renal failure patients. Nephron 1988;50(1):64-65.

16. Linthorst GE, Avis HJ, Levi M. Uremic thrombocytopathy is not about urea. J Am Soc Nephrol 2010;21(5):753-755.

17. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004;30(5):579-589.

18. Goldstein RE, Marks SL, Kass PH, et al. Gastrin concentrations in plasma of cats with chronic renal failure. J Am Vet Med Assoc 1998;213(6):826-828.

19. Langston CE, Reine NJ, Kittrell D. The use of erythropoietin. Vet Clin North Am Small Animal Pract 2003;33(6):1245-1260.

20. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1-14.

21. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649-659.

22. MacLeod JN. Species-specific recombinant erythropoietin preparations for companion animals, in Proceedings. ACVIM Vet Med Forum 2001.

23. MacLeod JN, Tetreault JW, Lorschy KA, et al. Expression and bioactivity of recombinant canine erythropoietin. Am J Vet Res 1998;59(9):1144-1148.

24. Wen D, Boissel JP, Tracy TE, et al. Erythropoietin structure-function relationships: high degree of sequence homology among mammals. Blood 1993;82:1507-1516.

25. Storring PL, Tiplady RJ, Gaines Das RE, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89.

26. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulation half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-299.

27. Harris D, Collins J, Disney A, et al. Darbepoetin alfa: a new erythropoietic drug for the treatment of renal anaemia. Nephrology 2002;7:S173-S180.

28. Macdougall IC. Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int 2002;(Suppl 80):S55-S61.

29. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008;3(1):200-207.

30. Blais MC, Berman L, Oakley DA, et al. Canine Dal blood type: a red cell antigen lacking in some Dalmatians. J Vet Intern Med 2007; 21(2):281-286.

31. Randolph JE, Scarlett J, Stokol T, et al. Clinical efficacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia. J Vet Intern Med 2004;18(1):81-91.

32. Randolph JE, Scarlett JM, Stokol T, et al. Expression, bioactivity, and clinical assessment of recombinant feline erythropoietin. Am J Vet Res 2004;65(10):1355-1366.

33. Burns DL, Mascioli EA, Bistrian BR. Parenteral iron dextran therapy: a review. Nutrition 1995;11(2):163-168.

34. Agarwal AK. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc 2006;7(9 Suppl):S7-S12.

35. Agarwal R. Iron, oxidative stress, and clinical outcomes. Pediatr Nephrol 2008;23(8):1195-1199.

36. Callan MB, Rentko VT. Clinical application of a hemoglobin-based oxygen-carrying solution. Vet Clin North Am Small Anim Pract 2003;33(6):1277-1293, vi.

37. Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 2001;86(11):5108-5117.

38. Harkin KR, Cowan LA, Andrews GA, et al. Hepatotoxicity of stanozolol in cats. J Am Vet Med Assoc 2000; 217(5):681-684.

39. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002;16:87-96.

40. Cowgill LD, James KM, Levy JK, et al. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J Am Vet Med Assoc 1998;212(4):521-528.

41. Pollock C, Johnson DW, Horl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008;3(1):193-199.

42. Cowgill LD. Application of recombinant human erythropoietin in dogs and cats. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XI. Philadelphia, Pa: WB Saunders, 1992;484-487.

43. Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005;106:3343-3347.

44. Rossert J, Macdougall I, Casadevall N. Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant 2005;20(Suppl 4):iv23-iv26.


ADVERTISEMENT

Source: VETERINARY MEDICINE,
Click here